FocusImmunotherapy

Twists and turns to translating 4-1BB cancer immunotherapy

See allHide authors and affiliations

Science Translational Medicine  12 Jun 2019:
Vol. 11, Issue 496, eaax4738
DOI: 10.1126/scitranslmed.aax4738

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Abstract

Previous shortcomings of CD137-targeted immunotherapy may be overcome by engineered bispecific agents (Claus et al., this issue).

View Full Text